865-299-6250 info@edpbiotech.com

KNOXVILLE, Tenn., May 28, 2019 /PRNewswire/ — EDP Biotech Corporation, an in vitro diagnostics developer focused on early detection of disease, today announced that it has entered into a non-exclusive agreement with Luminex Corporation. According to the terms, EDP Biotech will have the rights to develop, market and sell its blood-based colorectal cancer diagnostic assay, ColoPlex™, using Luminex’s xMAP® Technology.

The agreement supports the upcoming commercialization of ColoPlex, an inexpensive blood test which accurately detects early stage colorectal cancer and pre-cancerous polyps at the stage where such early detection leads to the best patient outcomes.

Read full Press Release HERE

Seeking Alpha subscribers can read more by clicking the icon below: